Autres langues Modus Therapeutics Holding AB

Actions

MODTX

SE0015987904

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:05:04 10/05/2024			Varia. 5j.	Varia. 1 janv.
1,05 ^SEK	-8,30%		+4,48%	-39,48%

21/02	Modus Therapeutics Holding AB (publ) annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI
2023	Modus Therapeutics va lancer une offre de droits de 40 millions de couronnes suédoises et émettre des actions pour compenser un prêt de 20 millions de couronnes suédoises	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Notice to Annual General Meeting in Modus Therapeutics Holding	17/04
Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2023	11/04
Modus Therapeutics publishes year-end report for 2023	21/02
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/02
The Rights Issue is Registered and Trading in Paid Subscribed Shares Ceases	13/12
Modus Therapeutics presented data on sevuparin demonstrating its potential to treat anemia in chronic kidney disease at the annual American Society of Hematology (ASH)	11/12
Modus Therapeutics Holding AB Announces Final Outcome in Rights Issue	05/12
Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue	14/11
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan	08/11
Modus Therapeutics Holding AB Conducts a Rights Issue of 40.3 MSEK and an Offset Issue of 20.3 MSEK	08/11
Modus Therapeutics publishes interim report for the third quarter 2023	08/11
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Modus Therapeutics to present at the 2023 American Society of Hematology Meeting and Exposition (ASH): New data on sevuparin and its potential to treat chronic kidney disease anemia and reduce kidney injury.	02/11
Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium in Barcelona	05/10/23
Modus Therapeutics publishes interim report for the second quarter 2023	23/08/23
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/08/23
Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic diseases at the annual European Hematology Association Congress	12/06/23
Modus Therapeutics to present at the annual European Hematology Association Congress, new data on sevuparin and its potential to treat anemia of chronic disease by suppression of hepcidin	12/05/23
Annual General Meeting in Modus Therapeutics Holding AB (publ)	11/05/23
Modus Therapeutics publishes interim report for the first quarter 2023	09/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Modus Therapeutics Holding AB

Actions

MODTX

SE0015987904

Autres langues

Filtres